follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
first-quart world-wide sale billion increas sale increas exclud
neg impact foreign exchang growth driven oncolog vaccin
sale china million first quarter increas sale china
increas exclud neg impact foreign exchang
strong gaap non-gaap ep growth first-quart
gaap ep first-quart versu first-quart includ
charg billion relat format collabor eisai co ltd
non-gaap ep first-quart versu first-quart
compani narrow rais full-year revenu rang billion
billion includ neg impact foreign exchang slightli
compani narrow rais full-year ep rang narrow
rais full-year non-gaap ep rang includ slightli
posit impact foreign exchang
keytruda approv food drug administr use combin axitinib first-
treatment patient advanc renal cell carcinoma
tuesday april edt
kenilworth -- busi -- merck nyse known msd outsid unit state
canada today announc financi result first quarter
strong start double-digit sale ep growth first quarter demonstr execut
across aspect busi strength key growth pillar includ oncolog vaccin said
kenneth frazier chairman chief execut offic merck invest research develop
pay confid science-driven strategi growth prospect abil sustain deliv
valu patient sharehold
million except ep amount
non-gaap net incom exclud certain
non-gaap ep exclud certain
refer tabl page
greater
world-wide sale billion first quarter increas compar first quarter
exclud neg impact foreign exchang world-wide sale grew sale
repres total sale quarter perform intern market led china
sale growth compar first quarter driven vaccin oncolog exclud
unfavor effect foreign exchang sale china grew
gener accept account principl earn per share assum dilut ep first
quarter non-gaap ep first quarter exclud acquisition- divestiture-rel
cost restructur cost net benefit settlement certain feder incom tax matter certain
merck continu advanc develop program keytruda pembrolizumab compani
therapi lynparza olaparib parp inhibitor co-develop co-commerci astrazeneca
lenvima lenvatinib mesyl oral avail tyrosin kinas inhibitor co-develop co-
commerci eisai co ltd eisai
merck announc food drug administr fda approv keytruda follow
first-lin treatment combin axitinib advanc renal cell carcinoma base
trial show combin reduc risk death nearli half
compar sunitinib
adjuv treatment patient melanoma involv lymph node follow
complet resect base result trial show
signific recurrence-fre surviv benefit keytruda
first-lin treatment patient stage non-smal cell lung cancer nsclc
candid surgic resect definit chemoradi metastat nsclc whose
tumor express tp egfr genom tumor aberr base
result trial
merck announc european approv keytruda combin chemotherapi first-lin
treatment metastat squamou nsclc base data trial
april european commiss approv six-week dose schedul across current
monotherapi indic keytruda
nation medic product administr china grantedcondit approv keytruda
first-lin treatment metastat nonsquam nsclc combin chemotherapi base
trial keytruda first therapi approv one tumor type
china first approv first-lin treatment set metastat nonsquam nsclc
merck announc fda grant prioriti review follow supplement biolog
licens applic keytruda seek use
first-lin treatment patient recurr metastat head neck squamou cell carcinoma
hnscc monotherapi combin chemotherapi base trial
fda set pdufa date june
third-lin treatment patient advanc small cell lung cancer sclc monotherapi base
trial fda set pdufa date june
merck announc initi three separ pivot phase trial patient metastat castration-
resist prostat cancer mcrpc evalu keytruda combin lynparza chemotherapi
anti-hormon agent
merck astrazeneca announc european approv lynparza treatment germlin brca-
mutat advanc breast cancer base phase olympiad trial
merck astrazeneca announc top-lin result polo studi lynparza reduc risk
diseas progress death first-lin mainten treatment germlin brca-mut metastat
pancreat cancer full result present upcom american societi clinic oncolog
merck announc fda accept prioriti review supplement new drug applic zerbaxa
ceftolozan tazobactam treatment adult patient nosocomi pneumonia includ
ventilator-associ pneumonia caus certain suscept gram-neg microorgan
pdufa date june applic also review indic european
medicin agenc ema applic base result phase aspect-np studi
recent present european congress clinic microbiolog infecti diseas
merck announc fda accept prioriti review new drug applic compani
investig beta-lactamas inhibitor relebactam combin imipenem/cilastatin treatment
certain infect caus certain suscept gram-neg bacteria adult limit
altern therapi avail pdufa date juli applic also review
ema
merck inc announc merck exercis option extend research
phase compani collabor march collabor focus discov
develop commerci novel biolog therapeut across rang therapeut area
merck announc ema recent accept market author applic rvsvg-
zebov-gp compani investig vaccin ebola zair diseas roll submiss
biolog licens applic fda underway
follow tabl reflect sale compani top pharmaceut product well sale anim health
million
proquad m-m-r ii
first-quart pharmaceut sale billion increas compar first quarter
exclud unfavor effect foreign exchang sale grew first quarter increas driven
primarili growth oncolog vaccin partial off-set on-going impact loss market exclus
sever product
growth oncolog driven signific increas sale keytruda reflect strong momentum
treatment patient nsclc compani continu launch new indic global
addit oncolog sale reflect allianc revenu million relat lynparza million relat
lenvima repres merck share profit product sale net cost sale commerci
growth vaccin driven larg higher sale gardasil papillomaviru quadrival type
vaccin recombin gardasil human papillomaviru vaccin recombin
vaccin prevent certain cancer diseas caus human papillomaviru hpv primarili due
on-going commerci launch china higher demand europ driven primarili increas vaccin rate
boy girl well time custom purchas latin america also contribut sale growth
growth partial off-set lower sale unit state reflect public sector buy pattern
growth pediatr vaccin driven varivax varicella viru vaccin live vaccin help prevent
chickenpox proquad measl mump rubella varicella viru vaccin live combin vaccin help
protect measl mump rubella varicella m-m-r ii measl mump rubella viru vaccin
live vaccin help prevent measl mump rubella reflect govern tender latin america
higher demand europ unit state
perform hospit acut care reflect strong demand unit state bridion sugammadex inject
mg/ml medicin revers neuromuscular blockad induc rocuronium bromid vecuronium
bromid adult undergo surgeri on-going launch prevymi letermovir medicin
prevent cytomegaloviru cmv infect diseas adult cmv-seroposit recipi allogen
pharmaceut sale growth quarter partial off-set on-going impact loss market
exclus zetia ezetimib vytorin ezetimibe/simvastatin medicin lower cholesterol
invanz ertapenem sodium antibiot cancida caspofungin acet inject antifung well
biosimilar competit remicad infliximab treatment inflammatori diseas compani market
territori europ addit sale januvia sitagliptin janumet sitagliptin metformin
medicin help lower blood sugar adult type diabet declin slightli due continu price
pressur unit state off-set strong demand intern market
anim sale total billion first quarter decreas compar first quarter
exclud unfavor effect foreign exchang anim health sale grew first quarter
sale perform reflect higher demand companion anim product primarili bravecto fluralan line
product parasit control volum growth livestock product particularli sale new poultri
swine product partial off-set lower rumin product sale driven distributor purchas pattern
delay movement cattl feedlot unit state
anim segment profit million first quarter essenti flat compar
million first quarter april merck acquir antelliq group leader digit anim
identif traceabl monitor solut
first-quart expens ep relat inform
tabl present select expens inform
million
sale
sell gener
research develop
sale
sell gener
research develop
gaap expens ep relat inform
gross margin first quarter compar first quarter increas
gross margin first quarter primarili driven lower acquisition- divestiture-rel cost
restructur cost reduc gross margin percentag point first quarter compar
percentag point first quarter addit gross margin impact favor effect
foreign exchang product mix partial off-set increas amort intang asset relat
collabor unfavor effect price pressur royalti
sell gener administr expens billion first quarter decreas compar
first quarter decreas primarili reflect lower promot sell cost favor effect
foreign exchang partial off-set higher administr cost
research develop expens billion first quarter compar billion
first quarter declin driven primarili billion charg record first quarter
relat format collabor eisai partial off-set higher expens relat clinic
develop includ collabor invest earli drug develop
incom expens net million expens first quarter compar million
incom first quarter incom expens net first quarter reflect unfavor
effect foreign exchang loss impair charg incom expens net first quarter
effect incom tax rate first quarter reflect net tax benefit million relat
settlement certain feder incom tax matter
gaap ep first quarter compar first quarter
non-gaap expens ep relat inform
non-gaap gross margin first quarter compar first quarter
increas non-gaap gross margin reflect favor effect foreign exchang product mix partial
off-set increas amort intang asset relat collabor unfavor effect
price pressur royalti
non-gaap sell gener administr expens billion first quarter decreas
compar first quarter decreas reflect lower promot sell cost favor
effect foreign exchang partial off-set higher administr cost
non-gaap expens billion first quarter increas compar first quarter
increas reflect higher expens relat clinic develop includ collabor invest
earli drug develop
non-gaap incom expens net million expens first quarter compar
million incom first quarter non-gaap incom expens net first quarter
non-gaap effect incom tax rate first quarter
non-gaap ep first quarter compar first quarter
reconcili non- net incom ep provid tabl follow
million except ep amount
non-gaap ep exclud item list
non-gaap net incom exclud item list
decreas increas net incom due exclud item
acquisition- divestiture-rel
aggreg charg relat format collabor eisai
net decreas increas incom tax
acquisition- divestiture-rel cost attribut non-controlling interest
decreas increas net incom
merck narrow rais full-year revenu rang billion billion includ
neg impact foreign exchang slightli mid-april exchang rate
merck narrow rais full-year ep rang merck narrow
rais full-year non-gaap ep rang includ slightli posit impact
foreign exchang mid-april exchang rate non-gaap rang exclud acquisition- divestiture-
relat cost cost relat restructur program net benefit settlement certain feder incom tax
matter certain item
follow tabl summar compani full year financi guidanc
billion
billion
lower mid-singl digit
higher low- mid-singl digit
compani non-gaap adjust revenu
ep guidanc assum share count assum dilut approxim billion share
reconcili anticip ep non- ep item exclud non- ep
provid tabl
million except ep amount
non-gaap ep exclud item list
acquisition- divestiture-rel
net decreas increas incom tax
decreas increas net incom
expect full-year effect tax rate reflect net favor impact approxim
percentag point item
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
today merck global health care leader work help world well merck known msd outsid
unit state canada prescript medicin vaccin biolog therapi anim health
product merck work custom oper countri deliv innov health solut
merck also demonstr commit increas access health care far-reach polici program
partnership
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
aenova group one world lead compani pharmaceut healthcar industri europ
aenova one lead contract manufactur rang servic cover entir valu chain
develop manufactur common dosag form solid semi-solid liquid product group
medicin dietari supplement group oper site nine european countri asia usa
twelv site headquart locat germani aenova employe
 braun one world lead healthcar supplier braun four divis orient product
servic toward differ medic field hospit surgeri privat practic medic care doctor offic
bayer innov compani histori core compet field health care
agricultur develop new molecul use innov product solut improv health
human anim plant bayer research develop activ base profound understand
biochem process live organ
boehring ingelheim group one world lead pharmaceut compani headquart
ingelheim germani boehring ingelheim oper global affili employe
focu family-own compani found research develop manufactur market
new medic high therapeut valu human veterinari medicin
umbrella tecdax-list compani carl zeiss meditec ag one world lead
medic technolog compani medic technolog activ zeiss bundl carl zeiss ag hold
interest carl zeiss meditec ag jena germani parent compani carl zeiss meditec
group compris addit subsidiari carl zeiss meditec inc carl zeiss meditec iberia
desitin arzneimittel gmbh activ intern germani switzerland scandinavia eastern europ level
hamburg plant produc sophist product treatment neurolog psychiatr ill
offer larg number establish innov product especi core indic epilepsi
parkinson syndrom optim pharmacotherapi continu develop cooper
future-ori compani treat diseas central nervou system one desitin main area
activ invest
freseniu global healthcar group offer high-qual product servic dialysi hospit
outpati treatment employe countri around globe annual sale
exceed billion freseniu one world lead healthcar compani freseniu group includ
four independ oper busi segment one activ major growth area healthcar freseniu
medic world leader treat peopl chronic kidney failur freseniu helio germani largest
hospit oper freseniu kabi suppli essenti drug clinic nutrit product medic devic servic
help critic chronic ill patient freseniu vame plan develop manag healthcar facil
freseniu medic world largest integr provid product servic individu undergo
dialysi chronic kidney failur condit affect around million individu world-wide
network dialysi clinic north america europ latin america asia-pacif africa freseniu
medic provid dialysi treatment patient around globe freseniu medic also
world lead provid dialysi product hemodialysi machin dialyz relat dispos
grnenthal group independ family-own intern research-bas pharmaceut compani
headquart aachen germani grnenthal one five remain research-ori pharmaceut
compani headquart germani sustain invest research develop research
develop cost amount percent revenu grnenthal research develop
strategi concentr select field therapi state-of-the-art technolog compani focus
discov new way treat pain better effect fewer side-effect current therapi
human healthcar togeth
merz pharma independ intern aesthet neurotoxin compani research
develop capabl continu growth market leadership aesthet neurotoxin result
drive innov along focus strateg acquisit continu expand across area
busi due focus purpos approach includ organ inorgan growth privately-
held family-own compani histori believ take long-term view
morphosi develop hucal success antibodi librari technolog pharmaceut industri
success appli patent technolog morphosi becom leader field
therapeut antibodi one
pharmaceut partner morphosi built therapeut pipelin human antibodi drug
candid treatment cancer rheumatoid arthriti alzheim diseas name
on-going commit new antibodi technolog drug develop morphosi focus make
healthcar product tomorrow morphosi list frankfurt stock exchang symbol mor
hartmann group one lead european provid medic hygien product core
compet wound treatment wound dress negative-pressur wound therapi conform bandag
plaster incontin care dispos incontin brief pad well product skin care case
incontin infect protect surgic drape oper theatr cloth dispos surgic
instrument disinfect portfolio supplement product compress therapi first aid
compani headquart heidenheim germani whose prioriti market europ oper around
world employe hartmann group gener sale eur million
engin innov employ peopl compani provid healthcar germani
harmon qualiti medic care sound busi model good busi judgment
tada publicli trade intern compani focu healthcar market
perfect combin tradit innov attract cost
germani best intern locat research product distribut pharmaceut
except high level direct access intern renown scientist outstand research unit major
pharmaceut market make germani uniqu busi locat develop world popul
structur creat new challeng lead increas demand pharmaceut togeth
signific advanc medic biotechnolog research give pharmaceut industri new impetu
addit central locat heart europ germani offer excel well-develop nationwid
infrastructur modern transport network work coordin high-qual commun
energi infrastructur hundr thousand highli qualifi worker area medic technolog
pharmaceut technolog mechan engin enabl compani implement effici complex
product process pharmaceut compani germani also benefit close proxim lead
machin plant manufactur ensur continu product process reduc downtim germani
account approxim total product machineri plant europ
research develop
germani becom one world import countri clinic studi germani leader
industry-initi clinic studi europ second world-wide dens network univers faculti
well varieti research institut affili univers speak favor germani busi locat
benefit assess review negoti problem conflict
legislatur creat act restructur pharmaceut market amnog includ difficult
compon term mandatori discount price moratorium earli benefit assess directli
massiv impact exist busi model especi procedur earli benefit assess
establish process complex complic place question
facilit easier categor individu aspect procedur develop interact
inform graphic cooper rztezeitung illustr process earli benefit assess
includ parti involv result problem conflict
associ research-bas pharmaceut compani vfa
earli german associ research-bas pharmaceut compani vfa
vfa repres interest global leader research-bas pharmaceut compani
subsidiari affili compani healthcar research econom polici
german associ pharmaceut industri bpi
servic provid compani field biotechnolog herbal medicin homeopathy/anthroposophi
german associ produc
member member among pharmaceut industri associ
germani member primarili pharmaceut produc also pharmacist lawyer publish agenc
well market opinion research institut healthcar field
generika associ compani manufactur gener biosimilar product germani
generika member compani germani compani manufactur gener biosimilar product
togeth cover percent medicin drug requir statutori health insur fund
bundesverband der arzneimittel-herstel german medicin manufactur associ
repres interest pharmaceut industri germani compris intern compani well
local small medium enterpris sme compani membership lead trade organ
pharmaceut industri germani
cover entir rang industri landscap self-med medicin over-the-counter prescript
drug rx medic devic
advoc secur respons self-med profession medic pharmaceut advic
therefor strongli support statutori protect owner-oper pharmaci primari institut
addit commit free fair clean advertis promot principl regist
activ take part public health polici discuss compet refer public author
policymak institut german healthcar sector
member inform relev regulatori legisl procedur nation european level
offer scientif hands-on advic scientif servic organ widi
repres member european level brussels-bas aesgp associ european
self-med industri furthermor associ wsmi world self-med industri feder
member associ contin
work pharmaceut compani germani greatli hamper recent year due legisl
measur sever step tighten discount regul caus legal mandat manufactur discount
tripl sinc addit discount increas substanti recent year base individu agreement
overal manufactur receiv half sell price drug sector statutori
health insur report increas spend last year expenditur pharmaceut actual decreas
main driver behind spend pharmaceut price actual decreas year
increas consumpt result age societi avail new improv pharmaceut
treatment sever life-threaten diseas
third shi expenditur eur billion total eur billion spent hospit treatment togeth
expenditur care doctor eur billion percent pharmaceut eur billion percent
make anoth third eur billion spent administr cost increas mandatori manufactur
discount result percent decreas expenditur pharmaceut compar
associ research-bas pharmaceut compani vfa
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
